Splenic Marginal Zone Lymphoma research hub

Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

This study compares two treatments for a type of slow-growing lymphoma called Splenic Marginal Zone Lymphoma (SMZL). It looks at whether a combination of two drugs, rituximab and zanubrutinib, works better and is as safe as rituximab alone for patients needing their first treatment.